References
- Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br. J. Cancer 82(5), 1009–1012 (2000).
- Livingston PO, Wong GY, Adluri S et al. Improved survival in Stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.Oncol. 12(5), 1036–1044 (1994).
- O'Brien ME, Saini A, Smith IE et al. A randomized Phase II study of 5RL172 (Mycobacterium vaccae combined with chemotherapy in patients with advanced inoperable nonsmall cell lung cancer and mesothelioma. Br. J. Cancer 83(7), 853–857 (2000).
- Assersohn L, Souberbielle BE, O'Brien ME et al. A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Clin.Oncol. (R. Coll. Radio].) 14(1), 23–27 (2002).
- Maraveyas A, Baban B, Kennard D et al. Possible improved survival of patients with Stage IV AJCC melanoma receiving 5RL172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann. axon°, 817–824 (1999).
- O'Brien ME, Anderson H, Kaukel E et al., SR-ON-12 Study Group. 5RL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced nonsmall cell lung cancer: Phase III results. Ann. Oncol. 15(6), 906–914 (2004).
- Palena C, Zhu M, Schlom J, Tsang KY. Human B-cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells. Blood 104(1), 192–199 (2004).
- Tsang KY, Palena C, Gulley J, Arlen P, Schlom J. A human cytotoxic T- lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUCl. Clin. Cancer Res. 10(6), 2139–2149 (2004).
- Dredge K, Marriott JB, Todryk SM et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Thl - type immunity. J. Immunol. 168(10), 4914–4919 (2002).